Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL SA versus FORADIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL SA versus FORADIL.
CHOLEDYL SA vs FORADIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Category C
Category C
Bronchodilator
Bronchodilator